This segment focuses on the development and sale of molecular diagnostic testing services for cancer. Response Genetics utilizes advanced molecular techniques to analyze tumor samples, providing oncologists with critical information to guide treatment decisions. Research and development activities include the continuous improvement and expansion of test offerings, focusing on identifying predictive factors for therapy response. Technologies employed include PCR-based assays and next-generation sequencing. The primary therapeutic areas are non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma, thyroid cancer, breast cancer, and glioma. The impact on patients is significant, as these tests help personalize treatment plans, potentially leading to improved outcomes and reduced side effects. The company's market positioning is based on its CLIA-certified laboratory and its focus on pharmacogenomic testing. Future opportunities lie in expanding the test menu and exploring new biomarkers. The company has partnerships with pharmaceutical companies and healthcare providers to facilitate the use of its tests.

This segment is dedicated to the research, development, and commercialization of pharmacogenomic tests. These tests are designed to measure predictive factors for therapy response in tumor tissue samples, enabling physicians to select the most effective treatments for individual patients. Research and development efforts focus on identifying and validating biomarkers that predict response to various cancer therapies. The company utilizes advanced molecular biology techniques, including RNA isolation and analysis, to develop its tests. The primary therapeutic areas include a wide range of cancers, such as lung, colorectal, breast, and melanoma. The patient impact is substantial, as these tests help to personalize cancer treatment, potentially improving outcomes and reducing adverse effects. The company's market position is strengthened by its CLIA-certified laboratory and its focus on molecular diagnostics. Future growth opportunities include expanding the test menu, developing companion diagnostics, and entering into strategic partnerships with pharmaceutical companies. Regulatory compliance and clinical validation are critical aspects of this segment.